Krystal Biotech (KRYS) Q3 2026 earnings review
Krystal Biotech profit rises, but its clinical trials slip into 2027
Krystal Biotech is generating more profit from its rare-skin-disease gel Vyjuvek even as its follow-on drug trials fall behind schedule. Third-quarter sales grew 30% to $127 million, and operating profit jumped 72% because overhead costs shrank. Chief executive Krish Krishnan announced a $400 million share buyback and cut the full-year operating expense plan by $25 million, leaving fourth-quarter spending flat from a year ago by our math.
| Vyjuvek product revenue | $127.3M +30% from a year ago |
|---|---|
| Operating profit | $71.1M +72% from a year ago |
| Share buyback programme | Up to $400M expected over two years |
| Full-year operating expense plan, excluding one-offs | Cut $25M new range: $155–165M |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because stronger commercial cash returns and European pricing wins offset another round of clinical pipeline delays. Finishing price talks in Germany and Italy removes a key overseas overhang, and the buyback finally puts $1.2 billion in cash to work. The bad news: five clinical milestones slipped into 2027, including both late-stage eye studies, and new US patient approvals slowed to about 30 from 35 last quarter.
The question now is whether international expansion and early skin-cancer data can make up for a maturing US market and slower late-stage trials. Supporters see a self-funding platform adding European countries, while skeptics see US treatment pauses and serial trial delays pushing new launches further out. The geographic sales split in the third-quarter filing and the February 2027 eye study visit will tell.
🐂 Bull Case
Lower Overhead and Delayed Trials Cut the Cost Plan
Krystal Biotech makes Vyjuvek, a topical gene-therapy gel for patients with dystrophic epidermolysis bullosa (DEB), a rare genetic blistering skin disease. Chief executive Krish Krishnan said "Continued growth in VYJUVEK revenue is supporting profitability and funding the advancement of our pipeline." In the third quarter, revenue rose while operating costs fell, so operating profit jumped.
- Product revenue: $127.3 million, up 30.2% from a year ago
- Selling and overhead costs: $33.7 million, down 11.9 percentage points of revenue to 26.5%
- Research and development costs: $14.9 million, down 3.2 percentage points of revenue to 11.7%
- Operating margin: 55.9%, up 13.6 percentage points from 42.3% a year ago
Because third-quarter spending excluding stock pay dropped 11% from a year ago to $34.7 million by our math, the biotech group cut its full-year expense plan by $25 million. That cost discipline lifts immediate cash generation, though part of the savings comes from clinical trials starting later than planned.
What to watch: fourth-quarter operating expenses excluding stock pay, implied at $42.4 million by our math. A figure near that mark will show whether late-stage trial costs are finally ramping up.
German and Italian Price Deals Clear the European Path
International rollouts in Germany, France and Japan have driven Krystal's sales growth this year, but temporary pricing in Germany forced the company to set aside revenue reserves. One standing concern has been that strict German pricing rules would cap the price across Europe, while supporters argued that Japanese and French assessments limited the risk.
This quarter, Krystal said "Pricing negotiations are now complete in both Germany and Italy". The gene-therapy maker plans to launch Vyjuvek in Italy in early 2027, expects a pricing decision in Spain later this year, and filed for approval in Australia.
Settling the German price removes the provisional reserve drag that held back European revenue in the first half. However, the press release did not disclose the final negotiated price or whether settling the reserve added a one-time boost to third-quarter revenue.
What to watch: the geographic revenue table in the third-quarter filing. It will show how much European and Japanese revenue grew above last quarter's $27.6 million and clarify any German pricing adjustment.
A $400 Million Buyback Puts Idle Cash to Work
Krystal had built up over $1.1 billion in cash and investments without a return plan, while employee stock options increased the share count by more than 3% from a year ago. Management had previously deferred buybacks until it had more clarity on pipeline costs.
The board has now authorized a share repurchase programme of up to $400 million, and Krishnan said "we expect to repurchase shares opportunistically over the next two years". Because the company cut its 2026 operating expense plan at the same time and generates over $70 million in quarterly operating profit, it can retire shares while still self-funding its clinical trials.
What to watch: actual share repurchases and diluted share count in the fourth-quarter report. Buying back shares will show management is actively offsetting employee stock dilution.
Gorlin Syndrome Pilot Shows 80% Lesion Regression
Beyond its approved skin gel, Krystal is testing KB113, an injected gene therapy for basal cell skin cancers in patients with Gorlin syndrome, a genetic disorder affecting over 10,000 Americans. In a three-patient pilot study, the company reported that "more than 80% of assessed BCC lesions showed investigator-assessed clinical regression".
Both injected and uninjected tumors shrank, which Krystal said is "consistent with an abscopal effect", meaning the local treatment triggered a broader immune response. Krystal has started talks with the Food and Drug Administration on late-stage development, and also won entry into the agency's Complex Innovative Trial Design programme for KB407, its inhaled cystic fibrosis candidate.
What to watch: the clinical trial design update for KB113 after FDA discussions conclude. A clear registrational path will add a fifth late-stage candidate to the pipeline.
🐻 Bear Case
Five Clinical Readouts Slipped Into 2027
Krystal aims to transform from a single-product business into a multi-product rare-disease company, and earlier this year it promised up to six clinical data readouts in 2026. Instead, trial timelines slipped across the pipeline again this quarter, leaving only the five-patient HALITE-1 skin study readout before year-end.
- KB803 (IOLITE eye study in DEB): top-line readout moved from Q4 2026 to shortly after February 2027
- KB801 (EMERALD-1 study in neurotrophic keratitis, a corneal nerve disease): 60-patient enrollment and readout moved from late 2026 to 2027
- KB407 (cystic fibrosis repeat-dose study): interim data moved from late 2026 to the first half of 2027
- KB111 (Hailey-Hailey skin disease): FDA meeting moved from late 2026 to Q1 2027, with 5 patients enrolled vs a target of 7
- KB707 (inhaled lung cancer chemotherapy combination): 70-patient enrollment moved from late 2026 to mid-2027
In KB803, Krystal enrolled three more patients, which "replaces two patients who withdrew for reasons unrelated to safety". In KB801, enrollment progressed "slower than initially anticipated" because patients already have an approved competing therapy and avoid a placebo trial. These delays push potential commercial launches further out.
What to watch: the last patient visit for the KB803 IOLITE study in February 2027. Any further patient withdrawals or delays in that small trial will push out Krystal's nearest drug approval.
US Patient Additions Slowed as Regional Split Waits
In the United States, older DEB patients and those with milder wounds often pause treatment once their skin heals, which reduced US revenue per approved patient by about 25% in the first half. Krystal no longer reports patient compliance rates, giving only cumulative US insurance approvals in its press release.
Total US reimbursement approvals reached "over 760" in the third quarter, up from 730 in the second quarter. By our math, that means Krystal added about 30 new US approvals, slowing from 35 additions in each of the prior two quarters and 40 a year ago. Because the release does not split US sales from international sales, readers cannot yet see whether US revenue kept shrinking.
What to watch: the US net product revenue line in the third-quarter 10-Q filing. A figure below last quarter's $91.6 million will show that treatment pauses and slower additions are still shrinking the home market.
Risks this quarter didn't answer
Four standing legal, commercial and strategic risks received no update in the third-quarter press release.
- Department of Justice subpoena into Krystal's sponsored genetic testing programme: open since early 2025; the quarterly filing's legal note will show if the status changed.
- KB407 patent inventorship lawsuit: filed in May 2026 over two cystic fibrosis delivery patents; the legal note in the 10-Q will provide any court updates.
- Single-product and customer concentration: Vyjuvek remains 100% of revenue; the filing will update how much of receivables sits with its top distributor.
- 2030 target of four marketed medicines and 10,000 patients: unmentioned again as registrational trial starts move into 2027.
👓 Other Themes
Year-Ago Tax Benefit Distorts Net Income Comparison
Headline net income fell 20.5% from a year ago to $63.1 million, and diluted profit per share dropped 22.9% to $2.05. That drop is entirely an accounting tax quirk: in the third quarter of 2025, Krystal booked a $31.4 million income tax benefit, compared with a $17.1 million tax expense this quarter. Before taxes, quarterly profit actually rose 67.1% to $80.1 million.
💲 Other KPIs
Total cash, short-term and long-term investments rose 8.3% from last quarter and 38.2% from a year ago by our math. Strong operating profit continues to build the balance sheet ahead of the new $400 million share buyback programme.
Gross margin — the share of sales left after the cost of making Vyjuvek — edged down 0.5 percentage points from last quarter and 1.6 percentage points from a year ago by our math, as cost of goods sold rose to $7.6 million from $4.3 million.
Weighted-average diluted shares rose 3.4% from a year ago and 0.6% from the second quarter. Stock-based pay totaled $13.9 million in the quarter, adding to the share count before the newly authorized buyback begins.
🔮 Guidance
Cut. Management lowered its full-year research and overhead spending plan (excluding stock-based pay) by $25 million at the middle of the range, to about 6.5% annual growth by our math. After $117.6 million spent in the first nine months, the new plan leaves $42.4 million for the fourth quarter, flat against a year ago. Krystal also cut its initial expense plan last year as clinical trial timelines slipped.
❓ Key Questions
What was the US vs international Vyjuvek revenue split?
The press release only reported global sales of $127.3 million. Investors need the geographic table from the 10-Q filing to see if US revenue recovered from its first-half decline or if overseas sales carried the entire beat.
Did completing German pricing trigger a one-time revenue adjustment?
Krystal had been setting aside conservative revenue reserves while negotiating German prices. Management did not say what final price it agreed to in Germany or whether settling past reserves boosted third-quarter sales.
Why did two patients withdraw from the registrational KB803 study?
Management replaced two patients who left the IOLITE eye study for non-safety reasons, pushing top-line results into early 2027. In a small trial using a patient-reported symptom score, any dropout mechanics matter for the outcome.
How will Krystal fix slow enrollment in the KB801 study?
Patients with neurotrophic keratitis already have an approved treatment, making it hard to recruit 60 patients into a placebo-controlled trial. Management pushed the readout into 2027 without saying whether it will relax the trial rules.